Eye Vision Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 97.30%
- Profit Growth 105.66%
- Ebitda 1802.25%
- Net Worth 34.77%
- Total Assets 64.54%
About Eye Vision Biotech
Eye Vision Biotech Private Limited (EVBPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 February 2018 (Six years and 11 months 10 days old ). Its registered office is in Chandigarh, India.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Srivastava, Ashish Srivastava, Santosh Gupta, and One other member serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999CH2018PTC041873
-
Company No.
041873
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Feb 2018
-
Date of AGM
25 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Eye Vision Biotech?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Srivastava
|
Director | 22-Feb-2018 | Current |
|
Ashish Srivastava
|
Director | 22-Feb-2018 | Current |
|
Santosh Gupta
|
Director | 22-Feb-2018 | Current |
|
Ashok Rai
|
Director | 23-Feb-2018 | Current |
Financial Performance of Eye Vision Biotech.
Eye Vision Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 97.3% increase. The company also saw a substantial improvement in profitability, with a 105.66% increase in profit. The company's net worth Soared by an impressive increase of 34.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eye Vision Biotech?
In 2021, Eye Vision Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eye Vision Biotech?
Unlock and access historical data on people associated with Eye Vision Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eye Vision Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eye Vision Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.